Essex Woodlands Health Ventures, a venture capital firm dedicated exclusively to healthcare investing, has raised USD900m for its latest fund, Fund VIII.
Essex Woodlands Health Ventures, a venture capital firm dedicated exclusively to healthcare investing, has raised USD900m for its latest fund, Fund VIII.
To capitalize on market dynamics and the continuing flow of innovation in the healthcare field, the firm will primarily make growth equity investments in companies with a rapidly expanding revenue base and venture investments in companies with breakthrough technologies.
As in each of the last two funds, it will invest across the spectrum of drug, device and service companies in North America, Europe and Asia.
Marty Sutter, a founder and managing director at Essex Woodlands Health Ventures, says: ‘Healthcare remains a highly attractive market for investing and the opportunities created by the market changes underway together with the rapidly growing need for capital make the timing of this fund particularly important. This latest fund and the extraordinary team of professionals behind it allow us to be a strong partner to high growth companies whose capital requirements will allow them to assume leadership positions in their field and to venture companies which need to validate and monetize their new technologies.’
With USD2.5bn under management, Essex Woodlands is one of the largest and oldest venture capital firms pursuing investments in pharmaceuticals, biotechnology, medical devices, healthcare services and health information technology.
Since its founding in 1985, it has been involved in the founding, investing, and/or management of over 100 healthcare companies ranging across all sectors, stages and geography. The team is comprised of 25 senior investment professionals with offices in Palo Alto, Houston, New York, and London.
